Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2012

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
Deviations:
no
GLP compliance:
yes (incl. QA statement)

Test material

Constituent 1
Chemical structure
Reference substance name:
Octahydrocyclopenta[c]pyrrole
EC Number:
227-114-5
EC Name:
Octahydrocyclopenta[c]pyrrole
Cas Number:
5661-03-0
Molecular formula:
C7H13N
IUPAC Name:
octahydrocyclopenta[c]pyrrole
Test material form:
gas under pressure: refrigerated liquefied gas

Test animals

Species:
rat
Strain:
Wistar
Sex:
male/female

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
formulation prepared daily within 6 hours prior to dosing
Duration of treatment / exposure:
28 days
Frequency of treatment:
once daily, 7 days per week, approximately the same time each day.
Doses / concentrationsopen allclose all
Remarks:
Doses / Concentrations:
0 mg/kg
Basis:
nominal in water
Remarks:
Doses / Concentrations:
30 mg/kg
Basis:
nominal in water
Remarks:
Doses / Concentrations:
130 mg/kg
Basis:
nominal in water
Remarks:
Doses / Concentrations:
600 mg/kg
Basis:
nominal in water
No. of animals per sex per dose:
5

Examinations

Observations and examinations performed and frequency:
Mortality (twice daily), clinical signs (once daily), body weight and feed intake (weekly), clinical pathology (end of study), organ weight, macro- and microscopic examinations.
Other examinations:
Functional observations were performed during week 4, between 1 and 3 hours after dosing.

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
no mortality ; piloerection and hunched posture at 600 mg/kg/d
Mortality:
mortality observed, treatment-related
Description (incidence):
no mortality ; piloerection and hunched posture at 600 mg/kg/d
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
slightly lower body weight gain at 600 mg/kg/d
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
no relevant effects
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
no effects observed
Description (incidence and severity):
no relevant effects
Clinical biochemistry findings:
no effects observed
Description (incidence and severity):
no relevant effects
Organ weight findings including organ / body weight ratios:
no effects observed

Effect levels

Dose descriptor:
NOAEL
Effect level:
ca. 130 mg/kg bw/day (nominal)
Sex:
male/female
Basis for effect level:
other: clinical signs, body weight effect and forestomach lesions at 600 mg/kg bw/day

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion